KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial.

Adriana Balduzzi, Evgenia Glogova, Christina Peters, Petr Sedlacek, Jean-Hugues Dalle, Franco Locatelli, Roland Meisel, Birgit Burkhardt, Jochen Buechner, Jacek Wachowiak, Marc Bierings, Raquel Staciuk, Stelios Graphakos, Tayfun Güngör, Akif Yesilipek, Peter Svec, Julia Palma, Gergely Krivan, Cristina Diaz-de-Heredia, Francesca Limido, Marc Ansari, Krzysztof Kalwak, Peter Bader, Marianne Ifversen

Haematologica 111(1) 122-134

PMID40820816
PMCIDPMC12775767
DOI10.3324/haematol.2025.287456
发表日期2025-08-18
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

In the randomized cohort of the international phase-III FORUM trial, which showed the superiority of total-body irradiation (TBI) over chemotherapy-based conditioning prior to hematopoietic stem cell transplantation (HSCT) for pediatric acute lymphoblastic leukemia (ALL), type of conditioning and remission phase, but not pre-HSCT minimal residual disease (MRD), were associated with outcome. We report the impact of MRD within the extended FORUM cohort. Patients (N=1,014) aged 4-21 years old, transplanted from a matched donor who had ≥1 MRD measurement prior to and/or 100 days and/or one year after HSCT were eligible. A threshold of 0.01% defined MRD positivity versus negativity. Prior to HSCT, 21% of patients were MRDpos. Three-year event-free survival (EFS) was 0.73 and 0.59 (P<0.001), and 3-year cumulative incidence of relapse (CIR) was 0.20 and 0.33 (P<0.001) in MRDneg and MRDpos patients, respectively. The level of MRD positivity pre-HSCT (<0.1% vs. ≥0.1%) did not significantly affect outcome. Pre-HSCT MRDneg and TBI/etoposide conditioning were associated with a 2-fold lower risk of relapse, whereas MRDpos had a 2-fold higher risk of any failure and/or death. No detrimental effect of MRDpos pre-HSCT could be demonstrated in patients with T-cell ALL. MRDpos versus MRDneg patients at day 100 had an EFS of 0.47 versus 0.77 (P<0.001) and a CIR of 0.51 versus 0.17 (P<0.001), respectively, but post-HSCT MRDpos did not necessarily imply relapse. In conclusion, the MRD status pre-HSCT and at day 100 post-HSCT was a strong prognostic factor for children transplanted for ALL in the extended FORUM cohort.

KM 提取结果

2 个 Figure · 16 个 KM 面板

进入结果中心
KM Figure8 个面板

Figure 2

Figure 2. Outcome according to minimal residual disease status at the time of hematopoietic stem cell transplantation . Overall survival (OS) (A), event-free survival (EFS) (B), cumulative incidence of relapse (CIR) (C), and transplant-related mortality (TRM) (D). EFS (E) and CIR (F) for the total body irradiation/etoposide (TBI/VP16) subgroup. EFS (G) and CIR (H) for the chemo-conditioning subgroup. HSCT: hematopoietic stem cell transplantation; MRD: minimal residual disease; PCR: polymerase chain reaction; pos: positive; SE: Standard Error; TBI: total body irradiation; VP16: etoposide.

A

OS

Figure 2 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

EFS

Figure 2 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

CIR

Figure 2 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

TRM

Figure 2 · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 1:flat topline artifact
查看结果
E

EFS

Figure 2 · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span曲线 2:short span
查看结果
F

CIR

Figure 2 · Panel F

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel F 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
G

EFS

Figure 2 · Panel G

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel G 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
H

CIR

Figure 2 · Panel H

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel H 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
KM Figure8 个面板

Figure 3

Figure 3. Outcome by minimal residual disease status at the time of hematopoietic stem cell transplantation according to immunophenotype. Overall survival (OS) (A), event-free survival (EFS) (B), cumulative incidence of relapse (CIR) (C), and transplant-related mortality (TRM) (D) for patients affected with B-lineage acute lymphoblastic leukemia (ALL). OS (E), EFS (F), CIR (G), and TRM (H) for those affected with T-lineage ALL. HSCT: hematopoietic stem cell transplantation; MRD: minimal residual disease; PCR: polymerase chain reaction; pos: positive; SE: Standard Error; TBI: total body irradiation; VP16: etoposide.

A

Overall Survival

Figure 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Event-Free Survival

Figure 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

Cumulative Incidence of Relapse

Figure 3 · Panel C

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel C 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
D

Transplant-Related Mortality

Figure 3 · Panel D

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel D 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
E

Overall Survival

Figure 3 · Panel E

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel E 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span曲线 2:short span曲线 2:off origin start
查看结果
F

Event-Free Survival

Figure 3 · Panel F

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel F 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span曲线 2:short span曲线 2:off origin start
查看结果
G

Cumulative Incidence of Relapse

Figure 3 · Panel G

quality_warning 待 EXE 对齐 预期 2 条 已提取 1 条

Panel G 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 2 条,实际恢复 1 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
H

Transplant-Related Mortality

Figure 3 · Panel H

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel H 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. CONsolidated Standards Of Reporting Trials diagram. CONSORT: CONsolidated Standards Of Reporting Trials. HSCT: hematopoietic stem cell transplantation; MRD: minimal residual disease; PCR: polymerase chain reaction; TBI: total body irradiation; VP16: etoposide.
非 KM Figure